Alliance Pharmaceutical has received Food and Drug Administration clearance for its Imagent cardiac ultrasound contrast agent. Imagent, formerly known as Imavist, has been approved for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve delineation of the endocardial borders, according to the San Diego-based vendor.
Imagent will be marketed by Alliance in partnership with healthcare products distributor Cardinal Health and healthcare communications firm inChord Communications. Alliance said that it will formally introduce Imagent at next week's meeting of the American Society of Echocardiography, being held in Orlando.
By AuntMinnie.com staff writersJune 3, 2002
Related Reading
Alliance nears approval for Imavist, March 1, 2002
Alliance nets $15 million investment, December 3, 2001
Alliance completes reverse stock split, October 18, 2001
Alliance to launch prostate imaging study, October 8, 2001
Alliance wins patent interference ruling against Nycomed, September 20, 2001
Copyright © 2002 AuntMinnie.com
